What is Abacus Bioscience?
Abacus Bioscience is at the forefront of developing first-in-class active immunotherapies designed to overcome immune tolerance. The company's scientific endeavors are primarily focused on tackling challenging conditions such as cancer and chronic infections. By pushing the boundaries of immunotherapy, Abacus Bioscience aims to deliver novel and effective treatment solutions for patients facing these critical health issues, thereby enhancing patient outcomes and contributing to medical advancements.
How much funding has Abacus Bioscience raised?
Abacus Bioscience has raised a total of $4.4M across 1 funding round:
Angel/Seed
$4.4M
Angel/Seed (2023): $4.4M with participation from Pack Ventures, Sahsen Ventures, and Alexandria Venture Investments
Key Investors in Abacus Bioscience
Pack Ventures
Pack Ventures is an investment firm rooted in the University of Washington ecosystem that provides early-stage capital and hands-on support. They focus on building transformative companies in the fields of AI, life sciences, and deep-tech.
Sahsen Ventures
Sahsen Home invests in mission-driven enterprises that support Earthbound life, focusing on both for-profit and not-for-profit sectors to maximize social impact. The company emphasizes the importance of life sciences, social justice, and environmental sustainability in its initiatives.
Alexandria Venture Investments
Alexandria Venture Investments is a key player in venture capital, likely focusing on innovative companies within the life sciences and biotechnology sectors, providing strategic financial backing for growth and development.
What's next for Abacus Bioscience?
The recent major strategic investment positions Abacus Bioscience for significant expansion and further development of its therapeutic pipeline. This enterprise-level funding suggests a transition into a scaling phase, enabling the company to accelerate clinical trials, broaden its research initiatives, and potentially explore new market opportunities. The strategic nature of this capital infusion indicates strong confidence from investors in Abacus Bioscience's long-term vision and its potential to disrupt the immunotherapy landscape.
See full Abacus Bioscience company page
